7-hydroxystaurosporine (UCN-01) preferentially sensitizes cells with a disrupted TP53 to gamma radiation in lung cancer cell lines

被引:1
|
作者
Xiao, HH
Makeyev, Y
Butler, J
Vikram, B
Franklin, WA
机构
[1] Yeshiva Univ Albert Einstein Coll Med, Dept Radiat Oncol, Bronx, NY 10461 USA
[2] Yeshiva Univ Albert Einstein Coll Med, Dept Radiol, Bronx, NY 10461 USA
关键词
D O I
10.1667/0033-7587(2002)158[0084:HUPSCW]2.0.CO;2
中图分类号
Q [生物科学];
学科分类号
07 ; 0710 ; 09 ;
摘要
Mutations in TP53 occur in more than 50% of the lung cancer patients and are associated with an increased resistance to chemotherapy and radiotherapy. The human lung adenocarcinoma cell lines A549 and LXSN contain a wild-type TP53 and were growth arrested at both the G(1)- and G(2)-phase checkpoints after irradiation. However, a TP53-disrupted cell line, E6, was arrested only at the G(2)-phase checkpoint. UCN-01 (7-hydroxystaurosporine), a CHEK1 inhibitor that abrogates the G(2) block, has been reported to enhance radiation toxicity in human lymphoma and colon cancer cell lines. In this study, UCN-01 preferentially enhanced the radiosensitivity of the TP53-disrupted E6 cells compared to the TP53 wildtype cells. This effect was more pronounced in cells synchronized in early G(1) phase, where the E6 cells showed a higher resistance to radiation in the absence of drug. These results indicate that the combination of UCN-01 and radiation can more specifically target resistant TP53 mutated cancer cells and spare TP53 wild-type normal cells. (C) 2002 by Radiation Research Society.
引用
收藏
页码:84 / 93
页数:10
相关论文
共 38 条
  • [31] UCN-01, 7-hydroxyl-staurosporine, inhibits kinase activity of cyclin-dependent kinases and reduces the phosphorylation of the retinoblastoma susceptibility gene product in A549 human lung cancer cell line
    Kawakami, K
    Futami, H
    Takahara, J
    Yamaguchi, K
    BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 1996, 219 (03) : 778 - 783
  • [32] Synergistic effect with APR-246 and standard chemotherapy in small cell lung cancer cells carrying smoking-associated TP53 mutations
    Mohell, Nina
    Fransson, Asa
    Alfredsson, Jessica
    von Euler, Mikael
    Bjorklund, Ulf
    Abrahmsen, Lars
    CANCER RESEARCH, 2016, 76
  • [33] Molecular Mode of Action and Role of TP53 in the Sensitivity to the Novel Epothilone Sagopilone (ZK-EPO) in A549 Non-Small Cell Lung Cancer Cells
    Winsel, Sebastian
    Sommer, Anette
    Eschenbrenner, Julia
    Mittelstaedt, Kevin
    Klar, Ulrich
    Hammer, Stefanie
    Hoffmann, Jens
    PLOS ONE, 2011, 6 (04):
  • [34] APR-246 reactivates mutant p53 in non-small cell lung cancer cell lines and sensitizes cells for CDDP treatment under normoxic and hypoxic conditions
    Deben, Christophe
    Deschoolmeester, Vanessa
    Wouters, An
    Van den Bossche, Jolien
    Jacobs, Julie
    Lardon, Filip
    Rolfo, Christian
    Pauwels, Patrick
    CANCER RESEARCH, 2015, 75
  • [35] Etoposide (VP-16) sensitizes p53-deficient human non-small cell lung cancer cells to caspase-7-mediated apoptosis
    Chiu, CC
    Lin, CHMY
    Fang, K
    APOPTOSIS, 2005, 10 (03) : 643 - 650
  • [36] Etoposide (VP-16) sensitizes p53-deficient human non-small cell lung cancer cells to caspase-7-mediated apoptosis
    C.-C. Chiu
    C.-H. M. Y. Lin
    K. Fang
    Apoptosis, 2005, 10 : 643 - 650
  • [37] Adenovirus-mediated mda-7 gene expression radiosensitizes non-small cell lung cancer cells via TP53-independent mechanisms
    Kawabe, S
    Nishikawa, T
    Munshi, A
    Roth, JA
    Chada, S
    Meyn, RE
    MOLECULAR THERAPY, 2002, 6 (05) : 637 - 644
  • [38] miR129-1 regulates protein phosphatase 1D protein expression under hypoxic conditions in non-small cell lung cancer cells harboring a TP53 mutation
    Yin, Hong-Lei
    Xu, Hong-Wei
    Lin, Qing-Yan
    ONCOLOGY LETTERS, 2020, 20 (03) : 2239 - 2247